bioihbjkbjnl/mcl2 huggingface dataset:
Action Observation and Motor Imagery Induced Hypoalgesia in Asymptomatic Subjects
Condition: Analgesia; Exercise
Study type: Interventional

Summary: 
      This study evaluates the influence of motor imagery and the observation of actions on pain
      perception. Participants in this study are asymptomatic subjects who will perform an IM and
      AO protocol of an aerobic exercise.
    

Detailed description: 
      Motor Imagery (MI) is defined as a dynamic mental process that involves the representation of
      an action, in an internal way, without its actual motor execution. The Action Observation
      (AO) evokes an internal, real-time motor simulation of the movements that the observer is
      perceiving visually. Both mental processes trigger the activation of the neurocognitive
      mechanisms that underlie the planning and execution of voluntary movements in a manner that
      resembles how the action is performed in a real manner. The phenomenon of exercise-induced
      hypoalgesia is well known. This is why it has been suggested that these techniques could
      produce pain modulation similar to that produced by real exercise.
    

Intervention name(s): Action Observation plus motor imagery; Motor imagery; Exercise plus action Observation and motor imagery
Intervention type(s): Behavioral; Behavioral; Behavioral
Intervention description(s): Action observation (video) and motor imagery of running.; Motor imagery of running; Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Motor imagery; Action observation; Hypoalgesia
The Oral Microbiome in OSCC
Condition: Oral Cancer
MeSH terms: Mouth Neoplasms
Study type: Interventional

Summary: 
      Previous work by a number of scientific teams has revealed that the types of bacteria that
      colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The
      purpose of this study is to investigate the extent of these changes and to correlate the
      changes with alterations in the activities of the host's own oral tissues. In doing so, we
      believe we can gain a better understanding of how particular bacterial species, or consortia
      of species, can result in an individual having an increased risk of the most common type of
      oral cancer -- oral squamous cell carcinoma. This knowledge may also lead to the
      identification of salivary biomarkers that can be used for clinical evaluation or screening.
      In addition, we seek to determine the extent to which a probiotic regimen can help prevent or
      rectify the disease-related changes in the types of bacterial colonizing the mouth. The
      microbiome in health, pre-cancerous lesions, and cancerous lesions will be determined from
      remnant microbial DNA in banked tissue samples. The effects of probiotics on the oral
      microbiome will be determined from DNA collected from swabs of oral tissue at baseline and
      then after 3 to 6 months of probiotic usage.
    


Intervention name(s): ProDentis Lozenge; Placebo Lozenge
Intervention type(s): Dietary Supplement; Other
Intervention description(s): 1-2 ProDentis Lozenges per day; 1-2 Placebo Lozenges per day
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Turkish Validity and Reliability of the Recovery Scale QoR-15
Condition: Health Behavior
Study type: Interventional

Summary: 
      It is adapted and encouraged to a point to improve their quality of intervention for the
      purpose of the research.
    

Detailed description: 
      This research was conducted as a methodological and descriptive study to evaluate the
      psychometric properties of the "Quality of Recovery Score" in patients who had surgery. The
      study was carried out with the participation of 150 patients over the age of 18 who were
      operated under general anesthesia in Samsun Training and Research Hospital between 8.11.2021
      and 3.01.2022.
    

Intervention name(s): Quality of Recovery Score
Intervention type(s): Other
Intervention description(s): Descriptive
Other intervention name(s): Turkish validity and reliability
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 2

Summary: 
      Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356
      BS (0.5 mg, 2.5 mg, and 10 mg) administered orally once daily for 28 days in Japanese
      patients with type 2 diabetes mellitus.
    


Intervention name(s): Low dose of BI 1356 BS; Medium dose of BI 1356 BS; High dose of BI 1356 BS; Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention MeSH terms: Linagliptin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
A Comparison of ESP Block to SSN Block for Analgesia in Shoulder Surgery
Condition: Arthroscopic Shoulder Surgery
Study type: Interventional

Summary: 
      A comparison between Erector Spinae Plane block and Suprascapular nerve block in providing
      analgesia for shoulder surgery
    

Detailed description: 
      Suprascapular nerve block is considered a phrenic nerve sparing approach that recently
      introduced as alternative for interscalene brachial plexus nerve block in shoulder surgery.
      However, some researchers reported that Suprascapular nerve block alone results in an
      ineffective analgesia. Erector Spinae Plane block is supposed to be able in providing
      adequate analgesia in shoulder surgery
    

Intervention name(s): Block procedures for shoulder surgery analgesia
Intervention type(s): Other
Intervention description(s): The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.
In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.
control group: patients will receive only general anesthesia
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: There has been a recent renewed interest in using the suprascapular nerve block (SSNB) as a phrenic nerve sparing approach for analgesia after shoulder surgery. The suprascapular nerve provides 70% of the sensory input to the glenohumeral joint and also innervates the infraspinatus and supraspinatus muscles. However, some researchers suggest that SSNB alone cannot provide a sufficient analgesia.The high-thoracic erector spinae plane block (HT-ESPB) has been described in several case reports as an effective analgesic modality for the shoulder region without causing motor or phrenic nerve block
Masking: Double (Care Provider, Outcomes Assessor)
Primary purpose: Other
Keywords: erector spinae plane block- suprascapular nerve
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants
Condition: Healthy Volunteer
Study type: Interventional
Phase: Phase 1

Summary: 
      This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      single and multiple oral doses of BIIB091 in healthy participants.This study will also
      determine the effect of food on the single oral dose pharmacokinetic (PK).
    

Detailed description: 
      Initial protocol recruitment and follow up was completed by 10 Jan 2020 with an optional
      cohort intended for completion by April 2020. Subsequently, a decision was made not to
      progress this optional cohort in light of COVID-19 which has resulted in a delay in reporting
      the actual completion date.
    

Intervention name(s): BIIB091; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Administered as specified in the treatment arm.; Administered as specified in the treatment arm.
Allocation: Randomized
Intervention model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Cytomegalovirus (CMV) Infection in Amniotic Fluid
Condition: Pregnancy Complications; Cytomegalovirus Infections
MeSH terms: Infections; Cytomegalovirus Infections; Pregnancy Complications
Study type: Observational

Summary: 
      The purpose of this study is to determine if detection of cytomegalovirus (CMV) in amniotic
      fluid collected in the second trimester of pregnancy is associated with pregnancy
      complications such as preterm delivery or severe preeclampsia.
    

Detailed description: 
      CMV infection in adults with a normal immune system is rarely a serious event. Once a person
      has been infected with CMV, they may have recurrences (relapses) of the infection. If a
      mother is infected with the virus or relapses during pregnancy, her fetus may be at risk for
      infection. Unlike infection in adults, congenital infection may result in serious
      complications (congenital infection). The effects of fetal infection with CMV are well
      understood and many efforts have been made to potentially reduce the risk of congenital
      infection. However, the effect of CMV infection on the pregnancy itself (when the fetus is
      not affected by CMV) is less understood.

      The incidence of CMV detection in amniotic fluid collected in the second trimester is thought
      to be low. However, the association between detection of CMV infection in the second
      trimester and ultimate pregnancy outcome is poorly described.

      In this study, we plan to determine if CMV detection in amniotic fluid collected in the
      second trimester is associated with pregnancy complications.
    

Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        The purpose of this study is to determine the prevalence of Cytomegalovirus (CMV) infection
        in amniotic fluid specimens obtained at 16 to 18 weeks of pregnancy and to determine if CMV
        infection of amniotic fluid supernatant and/or amniocytes is associated with adverse
        obstetric outcomes. Amniotic fluid will be obtained from an already established registry.
        and analyzed in conjunction with a chart review under a HIPAA Waiver of Authorization.
      
Keywords: Pregnancy; Cytomegalovirus
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
Condition: Condylomata Acuminata
MeSH terms: Condylomata Acuminata
Study type: Observational

Summary: 
      The summary of this study is to know which HPV types are present in genital warts in
      Argentinean population.
    

Detailed description: 
      This is a prospective study. Patients will be evaluated for the presence of external
      anogenital warts in our clinic. Biopsy will be performed if patients have genital lesions
      consistent with genital warts of the external genitalia or perianal area. All patients will
      be provided with an informed consent for the excision biopsy procedure, before performing the
      biopsy of the lesion. Biopsy specimens will be held in a formol 10% solution and will be sent
      to the pathologist. A portion of each sample will be processed for histological analysis,
      which will be performed by one pathologist. The remainder of each specimen will be saved to
      extract DNA for PCR analysis. All biopsies will be analyzed by the same pathologist who will
      confirm the histology of the lesion. A part of the specimen will be kept frozen and if the
      biopsy confirm genital warts by histology; then the specimen will be analyzed by PCR for the
      presence of DNA HPV 6 and 11. The PCR analysis will be done by microarrays. Detection is
      performed in a subtype of array platform system which detects the different types of virus.
      The reports will be as undetectable / detectable and type.

      The study will be conducted in the Institute of Gynecology and Fertility (Institute
      affiliated with the School of Medicine - University of Buenos Aires).

      Chronogram of activities: all activities will be done in a maximum of 60 days

        1. st visit: detect external genital warts and firm informed consent and take the biopsy

        2. nd visit: inform the result
    

Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Women with genital warts
      
Biospecimen description: 
      Biopsy specimens will be held in a formol 10% solution and will be sent to the pathologist. A
      portion of each sample will be processed for histological analysis, which will be performed
      by one pathologist. The remainder of each specimen will be saved to extract DNA for PCR
      analysis
    
Keywords: genital warts; HPV types; Sexually Transmitted Diseases; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Sexually Transmitted Diseases, Viral
Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
Condition: Multiple Sclerosis
MeSH terms: Multiple Sclerosis; Sclerosis
Study type: Interventional
Phase: Phase 2

Summary: 
      The primary objective was to estimate the tolerability and safety of 2 doses of teriflunomide
      administered once daily for 24 weeks, compared with placebo, in patients with multiple
      sclerosis [MS] with relapses who were on a stable dose of interferon-β [IFN-β].

      Secondary objectives were:

        -  to estimate the effects of the 2 doses of teriflunomide, compared to placebo, in
           combination with a stable dose of IFN-β on Magnetic Resonance Imaging [MRI] parameters,
           relapse rate and patient-reported fatigue;

        -  to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with
           a stable dose of IFN-β.
    

Detailed description: 
      The study period per participant was approximatively 44 weeks broken down as follows:

        -  Screening period up to 4 weeks,

        -  24-week double-blind treatment period*,

        -  16-week post-treatment elimination follow-up period.

      '*' participants successfully completing the week 24 visit were offered the opportunity to
      enter the optional long-term extension study LTS6047 - NCT00811395.
    

Intervention name(s): Teriflunomide; Placebo (for Teriflunomide); Interferon-β
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Film-coated tablet
Oral administration; Film-coated tablet
Oral administration; Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Other intervention name(s): HMR1726; Avonex®; Rebif®; Betaseron®
Intervention MeSH terms: Interferons; Interferon-beta; Teriflunomide; Interferon beta-1b
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: MS; interferon-beta; adjunctive therapy; relapses
Analgesia After Knee Arthroscopy :Dexmedetomidine vs Fentanyl
Condition: Analgesia
MeSH terms: Agnosia
Study type: Interventional

Summary: 
      The aim of this study is to evaluate analgesic effects Bupivacaine, Bupivacaine plus
      Dexmedetomidine and Bupivacaine plus Fentanyl in relieving pain after knee arthroscopic
      surgery.
    

Detailed description: 
      Forty-five patients ASA I - II aged 21-45 years for elective knee arthroscopy were divided
      into 3 groups: Group B, BD and BF. Group B received Intra-articular injection of 20 ml
      bupivacaine 0.25%+ 1 ml saline. Group BD received Intra-articular injection of 20 ml
      bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).

      Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug).
      The time of first request of analgesia and analgesic effect by VAS during the first 24 hr.
      postoperatively are recorded.
    

Intervention name(s): Dexmedetomidine; Fentanyl; Bupivacain
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).; Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug); Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
Other intervention name(s): precedex; marcaine
Intervention MeSH terms: Fentanyl; Dexmedetomidine; Bupivacaine
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: analgesia for postoperative pain after knee arthroscopy: dexmedetomidine+bupivacaine, fentanyl+bupivacaine , bupivacaine
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: dexmedetomidine; fentanyl; bupivacaine; knee arthroscopy; postoperative analgesia
Study on the Chronic and Acute Effects of Nordic Berry Beverage on Cognitive Function
Condition: Age-related Cognitive Decline
MeSH terms: Cognitive Dysfunction
Study type: Interventional

Summary: 
      The aim of the current study is to investigate whether acute and 12-weeks daily intake of
      Nordic berries can improve cognitive abilities of adults without cognitive disease, and
      whether the effect can be linked to changes in metabolic parameters.
    

Detailed description: 
      The study will be conducted with a randomized, double-blind, parallel-group (2 arms)
      placebo-controlled, single-center interventional design. The aim is to investigate the
      effects on cognitive function and cardiometabolic risk markers after acute and 12 weeks daily
      intake of a berry product vs. a reference product. The reference will be isocaloric and
      matched in taste, appearance, volume and macronutrient composition to the active berry
      product.

      Two groups, each of 30 volunteers, are studied. One group of volunteers will consume the
      berry product while the other group act as control and will consume the reference product.

      Each volunteer will be seen for a screening visit as well as one pre- and one
      post-intervention visit at the clinic. In addition, there will be 2 follow-up calls in
      between visits. Pre- and post intervention visits will include cognitive assessment with the
      CANTAB battery (episodic memory and verbal recognition memory), as well as additional
      cognitive and behavioral tests. Cardiometabolic parameters will be addressed (plasma glucose,
      insulin, inflammatory markers, blood lipids, body composition) and fecal samples collected.
    

Intervention name(s): Active berry product; Reference berry-like product
Intervention type(s): Other; Other
Intervention description(s): Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.; Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
Other intervention name(s): Inactive control
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Keywords: cognitive function; memory
Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam
Condition: Infections, Streptococcal; Streptococcus Pneumoniae Vaccines
MeSH terms: Pneumonia, Pneumococcal; Streptococcal Infections
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of the study is to evaluate the safety and reactogenicity of Synflorix™ (GSK
      1024850A) given as a 3-dose primary immunization course when co-administered with Infanrix
      hexa™ vaccine at 2, 3 and 4 months of age in infants in Vietnam.
    


Intervention name(s): Synflorix™( GSK1024850A); Infanrix hexa™
Intervention type(s): Biological; Biological
Intervention description(s): Intramuscular, 3 doses; Intramuscular, 3 doses
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Pneumococcal vaccine
Feasibility Pilot for the ReBOO-trial
Condition: Obesity
MeSH terms: Obesity
Study type: Interventional
Phase: Phase 2

Summary: 
      This is a pilot testing the feasibility of the 'REpurposing BOtulinum Toxin in Treatment of
      Obesity in Adolescents' trial (ReBOO-trial). The full-scale ReBOO will further investigate
      safety and efficacy of intragastric injections of botulinum toxin A into the antrum area of
      the stomach. These injections will be repeated every six months.

      The study sample will be adolescents with obesity who have not responded to standard
      conservative treatment.
    


Intervention name(s): Intragastric botulinum toxin type A
Intervention type(s): Drug
Intervention description(s): 200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
Other intervention name(s): Allergan
Intervention MeSH terms: Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Adolescent; Injections, intraperitoneal; Endoscopy; Botulinum Toxins, Type A; OnabotulinumtoxinA